EP
BCRX icon

Edgestream Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Edgestream Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$614K Buy
+61,446
New +$556K 0.02% 755
2023
Q3 		– Sell
-30,675
Closed -$216K – 819
2023
Q2 		$216K Buy
+30,675
New +$246K 0.02% 685

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Edgestream Partners's BCRX Position: Q2 2026 in Review

Edgestream Partners opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 61,446 shares worth $614K. The stake represents 0.02% of the portfolio and ranks #755 among its holdings. This is a return to the name: Edgestream Partners previously reported a position in BCRX as recently as Q2 2023.

Edgestream Partners first reported a position in BCRX in Q2 2023 and has held it in 2 quarters since. 319 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Edgestream Partners held 61,446 shares of BioCryst Pharmaceuticals worth $614K as of Q2 2026.
  • BioCryst Pharmaceuticals was a new Edgestream Partners position in Q2 2026.
  • BioCryst Pharmaceuticals made up 0.02% of Edgestream Partners's portfolio in Q2 2026, its #755 holding.
  • Edgestream Partners first reported a position in BioCryst Pharmaceuticals in Q2 2023 and has held it in 2 quarters since.
  • 319 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.